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What’s already known about this topic:  
- Linear morphoea (LM) is a rare connective tissue disorder 
- The underlying mechanism responsible for the fibrosis of LM is unknown. 
What does this study add: 
- LM fibroblasts from diseased skin possess a persistent, identifiable cell phenotype 
- LM fibroblasts display increased cell growth, and migration, and reduced response to TGF-β1. 
What is the translational message: 
- Cell-intrinsic changes in the LM fibroblast secretome lead to changes observed in the disease, 
- Secretome modulation could be a viable therapeutic approach in the treatment of LM. 
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ABSTRACT 
Background: Linear morphoea (LM) is a rare connective tissue disorder characterised by a line of thickened 
skin and subcutaneous tissue, and can also affect the underlying muscle and bone. Little is known about 
disease aetiology, with treatment currently limited to immune suppression, and disease recurrence post-
treatment is common.  
Objective: To uncover new therapeutic avenues, the cell intrinsic changes in LM fibroblasts compared to 
site-matched controls was characterised.  
Methods: We grew fibroblasts from site matched affected and unaffected regions from 5 linear morphoea 
patients, we subjected them to gene expression analysis and investigation of SMAD signalling. 
Results: Fibroblasts from LM lesions showed increased migration, proliferation, altered collagen processing, 
as well as abnormally high basal levels of phosphorylated SMAD2, thereby rendering them less responsive 
to TGF-β1 and reducing the degree of myofibroblast differentiation, a key component of the wound healing 
and scarring process in normal skin. Conditioned media from normal fibroblasts could reverse LM affected 
fibroblast migration and proliferation, suggesting that the LM phenotype is driven by an altered secretome. 
Gene array analysis and RNA-Seq indicated upregulation of ADAMTS8 and downregulation of FRAS1 and 
SOSTDC1. SOSTDC1 knockdown recapitulated the reduced TGF-β1 responsiveness and LM fibroblast 
migration, whilst overexpression of ADAMTS8 induced myofibroblast markers.  
Conclusions: We demonstrate that cell-intrinsic changes in the LM fibroblast secretome lead to changes 
observed in the disease, and that secretome modulation could be a viable therapeutic approach in the 
treatment of LM. 
 
 
Abbreviations: LM, linear morphoea; TGF-β, transforming growth factor beta; ECM, extracellular matrix; 
ADAMTS8, ADAM metallopeptidase with thrombospondin type 1 motif 8; FRAS1, Fraser extracellular matrix 
complex subunit 1; SOSTDC1, Sclerostin domain containing 1; ALK, activin receptor-like kinase; SMAD, 
mothers against decapentaplegic homolog; MMP, matrix metalloproteinase; α-SMA, α-smooth muscle actin; 
Keywords: Linear morphoea, fibrosis, migration, proliferation, secreted proteins, TGF-β 
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INTRODUCTION 
The fibrotic disorder of linear morphoea (LM) represents the most prevalent subtype of localised scleroderma 
(morphoea) in children [1]. Morphoea can be classified according to clinical phenotype which include the 
plaque, generalised, linear, and deep subtypes. LM typically occurs in childhood with its prevalence being 
greater in the young relative to systemic scleroderma (systemic sclerosis) [2]. Almost entirely restricted to 
tissues descended from the mesoderm, it possesses a distinct gene signature distinguishable from most 
systemic scleroderma samples in spite of sharing the principal pathology of dysregulated collagen production 
and degradation [1,3]. Consequently, the disease displays thickening and hardening of the skin [2]. In addition 
to the dermis, the underlying subcutaneous tissue, bone and central nervous system are also susceptible [1]. 
Disease progression begins with an inflammatory phase followed by skin hyperaemia, fibrosis, sclerosis and 
lastly tissue atrophy [2]. The poor heritability of the disease, with no identified gene defect, suggests that it is 
a multivariant disorder, with possible risk factors including a family history of autoimmune disease or 
environment events. The disease also shows an approximate 2.5:1 bias toward females [2]. There is 
indication that this disease is a consequence of genetic mosaicism as the lesions correlate with the lines of 
Blaschko [2]. Novel treatment modalities could be informed by the specific gene expression differences 
between the affected and unaffected regions of the skin. 
Fibrosis involves the production of extracellular matrix (ECM) constituents such as collagens during the 
physiological wound healing process as well as in pathologies of excessive or aberrant scarring. The 
fibroblast is responsible for the organisation of the ECM and represents a critical component of fibrogenesis. 
Fibroblasts are activated by mechanical stress to form proto-myofibroblasts, which with the addition of the 
ED-A splice variant of fibronectin and transforming growth factor-β1 (TGF-β1) differentiate into α-smooth 
muscle actin (α-SMA) expressing myofibroblasts [4]. The myofibroblast is the principal ECM producing cell 
and their persistence in most fibro-contractive diseases highlights their important regulatory role in resolving 
fibrotic processes [4]. 
TGF-β1 is a significant facilitator of the fibrosis of many tissues and mediates numerous processes that cover 
differentiation, proliferation, migration, and apoptosis [5]. TGF-β1 is synthesised as a precursor which is 
cleaved intracellularly to produce the latency-associated peptide from the N-terminus and the TGF-β1 
homodimer from the C-terminus [6]. Proteolytically activated TGF-β1 binds and induces phosphorylation in 
its cognate receptor consisting of the TGF-β type I (TβRI) and TGF-β type II (TβRII) homodimers [7]. 
Canonical TGF-β1 signalling is mediated by the specific TβRI activin receptor-like kinase (ALK) 5, which 
upon activation leads to the recruitment and phosphorylation of the receptor-regulated mothers against 
decapentaplegic homolog (SMAD) 2 and 3 [7]. The receptor-regulated SMADs then complex with the 
common-mediator SMAD4 and translocate into the nucleus to control gene expression [5]. 
The underlying mechanism responsible for the fibrosis of LM is unknown. The aim of this study was to improve 
understanding of the disease by investigating phenotypic differences between fibroblasts isolated from LM 
lesions and normal skin regions. Gene expression analysis was performed to identify possible mediators of 
these distinct disease phenotypes, followed by subsequent over- and underexpression of selected genes to 
identify potential therapeutic targets. We show that LM fibroblasts from diseased skin possess a persistent, 
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identifiable cell phenotype in culture exhibiting increased cell growth, increased migration, and paradoxically 
a reduced response to TGF-β1. Knockdown and overexpression studies demonstrated that dysregulation of 
the secretome underlies the phenotype of LM fibroblasts. 
MATERIALS AND METHODS 
Cell culture 
Human primary dermal fibroblasts were isolated from punch biopsies of affected (A) areas and site-matched 
normal (N) regions of consented patients with linear morphoea (Table 1) by trypsin/collagenase digestion 
(Sigma-Aldrich) and were subsequently expanded. Human primary dermal fibroblasts and mouse NIH 3T3 
fibroblasts were cultured in DMEM (low glucose; Sigma-Aldrich) supplemented with FBS (10% v/v; 
ThermoFisher Scientific) and Antibiotic-Antimycotic (1% v/v; ThermoFisher Scientific) in a humidified 
atmosphere of 5% CO2 and 95% air at 37°C, with media changes occurring thrice weekly. Cells from passage 
3-7 were used in experiments. 
Stimuli and inhibitors 
Cells were serum-starved overnight and treated in serum-free culture media. Detection of α-SMA-expressing 
fibroblasts was conducted by 48 h serum-reduction in culture media containing FBS (0.1% v/v). Cells were 
treated with the growth factor TGF-β1 (12.5 ng/ml; Sigma-Aldrich) in media additionally containing BSA (0.1% 
w/v; Sigma-Aldrich), the DNA synthesis inhibitor mitomycin C (10 μg/ml; Sigma-Aldrich) with a 30 min pre-
incubation. Control vehicles were culture media plus BSA (0.1% w/v) in place of TGF-β1, and dimethyl 
sulphoxide (DMSO; 0.1% v/v; Sigma-Aldrich) in place of the inhibitors. Conditioned media was generated by 
serum-starving cells for 24 h followed by 2 rinses in PBS (MP Biomedicals) and incubating cells with serum-
free media for 24 h; this was mixed 1:1 with fresh serum-free DMEM before application to replenish depleted 
nutrients. 
Transfection and transduction of fibroblasts 
Mouse NIH 3T3 fibroblasts were stably transfected with Lipofectamine 2000 (Invitrogen) with mouse Sostdc1 
(NM_025312) SureSilencing shRNA Plasmids (Qiagen), or scrambled sequence negative control plasmids 
(Qiagen) according to manufacturer’s instructions. Cells were selected in fresh complete media containing G 
418 (400 μg/ml; Sigma-Aldrich) and were maintained in G 418 (200 μg/ml). Sostdc1 protein levels in 
conditioned media were assessed following PNGase F (New England Biolabs) treatment for 1 h to remove 
glycosylations. 
Linear morphoea normal primary dermal fibroblasts were stably transduced with: ADAMTS8 (NM_007037) 
Human LentiORF Particles (pLenti-C-mGFP-P2A-Puro; OriGene) for overexpression, or LentiORF Control 
Particles (pLenti-C-mGFP-P2A-Puro; OriGene) as an empty vector control. Cells at ~50% confluency were 
incubated overnight in complete media with polybrene (8 μg/ml; Sigma-Aldrich) at an MOI of 6. Subsequently, 
the lentivirus-containing media was replaced with fresh complete media for 24 h. Cells were then selected in 
fresh complete media plus puromycin (2 μg/ml; Sigma-Aldrich) according to a puromycin titration (data not 
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shown) to select for successfully transduced cells. After ~10 days, with selection media being replaced 
routinely every 3-4 days, puromycin-resistant colonies were expanded and used in experimentation. 
BrdU incorporation proliferation assay 
Cells were seeded in triplicate into a 96 well microplate at a density of 1 × 103 cells/cm2, cultured overnight 
and BrdU incorporation with visualisation by peroxidase was assayed according to manufacturer’s 
instructions (Millipore). Absorbance (450 nm) was detected with the Multiskan EX spectrophotometer 
(Thermo Scientific). 
Scratch motility assay 
Cells were seeded in triplicate into 6 well plates at a density of 5 × 104 cells/cm2 and cultured overnight. 
Confluent cells were pre-incubated for 30 min with mitomycin C (10 μg/ml) to inhibit proliferation, scratched 
with a 20 μl pipette tip, rinsed twice in serum-free DMEM to remove cell debris, and then incubated in DMEM 
containing mitomycin C (10 μg/ml) plus additional treatments. Images were taken in triplicate for each 
condition with the Olympus IX71 inverted microscope and HCImage Live (v4.3) capture software at 0 h to 
acquire baseline images, and at the experiment end-point of 24 h. Image analysis was conducted using the 
Fiji distribution of ImageJ (v1.51n). The denuded area was measured using the ‘Polygon Selection’ tool. End-
point data was normalised to the denuded area at 0 h. 
Adhesion assay 
Cells were seeded into a 96 well microplate at a density of 1 × 104 cells/cm2, cultured overnight, and 
treatments applied. At the experiment end-point, non-adherent cells were removed by rinsing in PBS and the 
microplate was then frozen at −70°C for at least 24 h to allow for efficient cell lysis. The microplate was 
thawed and incubated for 5 min, protected from light, with a solution of the nucleic acid fluorescent dye 
CyQUANT GR (1×, excitation: 485 nm, emission 520 nm; ThermoFisher Scientific) and Cell Lysis Buffer (1×; 
ThermoFisher Scientific) according to the manufacturer’s instructions. The sample fluorescence was then 
measured with the FLUOstar OPTIMA fluorescence plate reader (BMG Labtech). 
Collagen gel contraction assay 
Into 6 well plates 1 × 105 cells/well were mixed with a solution of Bovine Collagen I (4 mg/ml; Invitrogen) and 
Hank’s Balanced Salt Solution (1×, pH 7.2; Sigma-Aldrich), seeded and allowed to set at 37°C in a stainless 
steel washer (135 mm), which was subsequently removed. Baseline 0 h images and day 8 end-point images 
were acquired using the Leica DFC320 microscope (Leica Microsystems). Gel contraction was measured as 
gel area at day 8 normalised to the initial gel area of 0 h images using the Fiji distribution of ImageJ. 
TGF-β1 ELISA 
Secreted TGF-β1 in 24 h conditioned media was determined using the Human/Mouse TGF beta1 ELISA 
Ready-SET-Go! (2nd Generation; eBioscience) according to manufacturer’s instructions. Absorbance (450 
nm) was detected with the Multiskan EX spectrophotometer. 
Immunofluorescence 
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Paraffin-embedded tissue sections (5 μm) were prepared with standard protocols. To study 
immunofluorescence in vitro, cells on coverslips were fixed and permeabilised for 10 min in a warm solution 
of PFA (4% v/v) and Triton X-100 (0.1% v/v; Sigma-Aldrich), followed by a 5 min wash in PBS. Tissue sections 
and in vitro samples were blocked for 30 min or 1 h, respectively, in Fish Skin Gelatin (0.8 % v/v; Sigma-
Aldrich) plus Triton X-100 (0.2 % v/v). Primary antibodies (SOSTDC1, 1:500, Abcam; ACTA2, 1:500, Dako; 
p-SMAD2, 1:250, Cell Signaling Technology; p-SMAD2,3, 1:250, Cell Signaling Technology; ADAMTS8 2H5, 
1:100, Novus Biologicals; FRAS1 H-300, 1:200, Santa Cruz Biotechnology) diluted in blocking buffer were 
incubated at 4°C overnight. Sections and cells were washed in PBS-Tween 20 (PBS-T, 0.1% v/v; Sigma-
Aldrich) and then incubated at room temperature for up to 1 h with Alexa Fluor-conjugated secondary 
antibodies (1:500; Invitrogen) diluted in blocking buffer. Sections and cells were mounted in ProLong Gold 
Antifade Mountant with DAPI (Invitrogen). Images were acquired with Micro-Manager (v1.4.21) software and 
analysis was performed with the Fiji distribution of ImageJ. Picrosirius red histology was imaged using an 
epifluoresence microscope with side illumination. 
Western blotting 
Protein lysates were harvested on ice by scraping and vortexing with lysis buffer [Tris-HCl (20 mM), pH 7.5, 
NaCl (150 mM), EDTA (1 mM), Triton X-100 (1% v/v), sodium deoxycholate (0.5% w/v), SDS (0.1% w/v), 
protease inhibitor cocktail (1×; Roche), phosphatase inhibitor cocktail (2×; Roche)]. Protein concentration 
was quantified with the Bradford Protein Assay (Bio-Rad). Equal amounts were electrophoresed in Mini-
PROTEAN TGX Precast Protein Gels (4-20%; Bio-Rad) in Tris-Glycine-SDS buffer [1×, Tris base (0.25 M), 
glycine (1.92 M), SDS (1% w/v); Scientific Laboratory Supplies]. Proteins were transferred onto Amersham 
Protran Nitrocellulose Blotting Membranes (0.45 μm; GE Life Sciences) with Pierce Western Blot Transfer 
Buffer (ThermoFisher Scientific). Membranes were blocked for 30 min in dried skimmed milk (5% w/v; Marvel) 
in PBS-T and incubated at 4°C overnight with primary antibodies (p-SMAD2, 1:250, Abcam; SMAD2, 1:500, 
Cell Signaling Technology; p-SMAD3, 1:250, Cell Signaling Technology; SMAD3, 1:250, Cell Signaling 
Technology; MMP-2, 1:250; Alpha Smooth Muscle Actin, 1:250, Abcam; ADAMTS8 2H5, 1:500, Novus 
Biologicals; FRAS1 H-300, 1:200, Santa Cruz Biotechnology; GAPDH, 1:2000, Merck-Millipore). 
Subsequently, membranes were subjected to 5 min washes in PBS-T and then incubated with HRP-
conjugated secondary antibodies (1:3000; Dako). Membranes were visualised with the Amersham ECL 
Prime detection kit (GE Life Sciences) and Hyperfilm ECL (GE Life Sciences). Densitometry was performed 
with the Fiji distribution of ImageJ. 
Gelatin zymography 
Equal volumes of 24 h conditioned media aspirated from 1 × 106 cells for each condition were separated by 
non-denaturing electrophoresis in a gelatin (0.5% w/v) acrylamide-bis-acrylamide gel (7.5% w/v), and then 
incubated for 24 h at 35°C in enzymatic reaction buffer [Tris-HCl (0.05 M), pH 7.4, NaCl (20 mM), CaCl2 (5 
mM), NaN3 (0.02% w/v)] to allow digestion of gelatin. The gel was stained with Coomassie Brilliant Blue R-
250 Dye (ThermoFisher Scientific) at room temperature for ~10 min to detect undigested regions and was 
subsequently destained with a solution of methanol (30% v/v) and acetic acid (10% v/v). MMP bands were 
7 
discerned by protein size with reference to a protein ladder. Conditioned media run in gels lacking gelatin 
and stained with Coomassie Brilliant Blue R-250 Dye was used as a loading control. 
Microarray analysis and RNA sequencing 
Total RNA was extracted from low passage number cells and DNase treated with the RNeasy kit according 
to manufacturer’s instructions (Qiagen). RNA quality was assessed with a Nanodrop 2000c 
spectrophotometer (Thermo Scientific) and an Agilent Bioanalyser 2100 (Agilent Technologies). Total RNA 
(~2 μg) from each sample was used to generate double-stranded cDNA using a T7-oligo (dT) primer. 
Biotinylated cRNA, produced by in vitro transcription, was fragmented and hybridised to an Affymetrix Human 
Genome U133 Plus 2.0 microarray (48,000 probesets; ThermoFisher Scientific). The arrays were processed 
with a GeneChip Fluidics Station 450 (ThermoFisher Scientific) and scanned on an Affymetrix GeneChip 
Scanner (ThermoFisher Scientific), according to standard protocols. Expression signals were normalised to 
remove background noise and non-biological variations amongst arrays. Background noise was removed 
from the PM probe intensities using the “RMA” method. Primary data was calculated using both Microarray 
Analysis Suite (v5.0; Affymetrix) including mismatch probeset controls and GC-RM (quantile normalised). 
RNA-Seq was performed by UCL Genomics with libraries being synthesised from total RNA (2 μg) with an 
RNA integrity value of > 8 in all cases; libraries were sequenced with a 36 bp paired end read. The generated 
FastQ files were mapped against the Homo sapiens reference sequence GRCh37/hg19 using Bowtie, 
TopHat and SAMtools; duplicate reads were removed with SAMtools and read counts per gene were 
generated using HTSeq-count. EdgeR (Bioconductor) was used to normalise gene expression and generate 
lists of differentially expressed genes (DEGs). DEGs altered at least 2-fold in expression with P value < 0.05 
in ≥ 4 of 5 sample pairs. This trimmed data set was then analysed by DAVID for gene ontology (GO) term 
enrichment with Bonferroni correction for multiple testing. 
RESULTS 
LM fibroblasts are hyperproliferative, hypermigratory, with altered collagen processing 
Tissue harvested from LM patients of affected lesions and site-matched normal skin was stained with 
haemotoxylin and eosin. There were clumps of vimentin positive fibroblasts in the reticular dermis distal from 
the epidermis in affected dermis, but overall numbers of fibroblasts were unchanged.  Collagen arrangement 
was altered in the dermis according to picrosirius red staining  (Figure 1A). Differences between LM 
fibroblasts from normal and affected areas were investigated using primary human dermal fibroblasts isolated 
and cultured in vitro (Table 1). Given the relative increased presence of fibroblasts in affected regions, 
proliferation was studied by performing cell counts on fibroblasts initially seeded at equal densities and 
cultured for 3, 6, 8 and 10 days. At day 10, affected fibroblasts exhibited a greater cell number relative to 
normal fibroblasts cultured for 10 days (Figure 1B). BrdU incorporation into proliferating cells was increased 
relative to normal fibroblasts (Figure 1C).  
Fibroblast motility was investigated with a scratch assay. The denuded area at 24 h post-scratch with affected 
fibroblasts was reduced compared to normal fibroblasts indicating increased relative migration (Figure 1D). 
Activated fibroblasts involved in scar formation during wound healing and fibrotic pathologies exhibit an 
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increase in the capacity to contract collagen gels [8,9]. However, affected fibroblasts demonstrated a 
diminished capacity to contract collagen gels relative to normal fibroblasts (Figure 1E). TGF-β1 is integral to 
the development of differentiated myofibroblasts and, consequently, is critically implicated in fibrosis [10,11]. 
Conditioned media supernatant harvested after 24 h incubation with normal and affected LM fibroblasts did 
not contain differing levels of secreted TGF-β1 as detected by ELISA (Figure 1F). 
Matrix metalloproteinases (MMPs) such as MMP-2 are increased in expression and activity in activated 
fibroblasts [12]. Western blot analysis of conditioned media from affected fibroblasts displayed modestly 
(1.3X) increased levels of MMP-2 protein relative to normal fibroblasts (Figure 1G). Additionally, affected 
fibroblasts demonstrated significantly greater MMP-2 activity relative to normal fibroblasts when conditioned 
media was subjected to gelatin zymography (Figure 1G and H). Taken together, LM fibroblasts are 
hyperproliferative, hypermigratory and have higher levels of collagen processing than fibroblasts at site-
matched normal regions of the same individual. 
Altered response to TGF-β1 on the proliferation and adhesion of LM fibroblasts 
TGF-β1 mediates various cellular processes of fibroblasts [13]. To assess the potential modulation of LM 
fibroblast phenotype, cells were treated with TGF-β1 (12.5 ng/ml) for 24 h and proliferation was assayed by 
BrdU incorporation. Although BrdU levels in affected fibroblasts were elevated in comparison to normal 
fibroblasts, this relative increase was attenuated by TGF-β1 treatment (Figure 2A). 
To explore the effect of secreted factors on LM fibroblast motility, cells were incubated with culture media 
conditioned for 24 h with the opposite fibroblast type (i.e. normal on affected cells or affected on normal cells) 
following a scratch in the presence of mitomycin C (10 μg/ml). The increased motility of affected fibroblasts 
relative to normal fibroblasts was reduced when the culture media was replaced with that conditioned by 
normal fibroblasts (Figure 2B). Conditioned medium from affected fibroblasts had no effect on motility of 
normal fibroblasts (Figure 2B). The influence of a fibrotic environment on the adhesion ability of LM fibroblasts 
was investigated by incubating cells for 24 h with either TGF-β1 (12.5 ng/ml) or media conditioned for 24 h 
with the opposite fibroblast type. Non-adherent cells were removed by rinsing in PBS and remaining cells 
were assessed by incubation with the nucleic acid fluorescent dye CyQUANT GR. The adhesion of affected 
fibroblasts was significantly lower than of normal fibroblasts (Figure 2C). TGF-β1 treatment decreased normal 
fibroblast adhesion without altering the reduced adhesion of affected fibroblasts further (Figure 2C). 
Conditioned media incubation greatly decreased normal fibroblast adhesion and consequently demolished 
the difference relative to affected fibroblasts (Figure 2C). Therefore, proliferation and adhesion along with the 
resulting response to TGF-β1 treatment are altered in affected fibroblasts. 
The differentiated myofibroblast, whose persistence is central to the fibrotic lesions of many disorders, is 
typified by the expression of α-SMA [10]. LM lesion-associated fibroblasts demonstrated increased α-SMA 
relative to normal fibroblasts (Figure 2E). TGF-β1 (12.5 ng/ml) treatment for 24 h increased α-SMA protein 
in normal fibroblasts, whereas this was limited in affected fibroblasts (Figure 2E). Affected fibroblasts also 
displayed less α-SMA immunofluorescence staining 24 h post-scratch wounding relative to normal fibroblasts 
(Figure 2F). 
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TGF-β1 signalling can occur through distinct pathways that involve SMAD2/3 [14]. Affected LM fibroblasts 
displayed a reduced level of SMAD2 immunofluorescence staining 30 min post-scratch wounding relative to 
normal cells (Figure 2D). To better understand this differential response of LM fibroblasts following TGF-β1 
stimulation, downstream SMAD signalling was investigated. In unstimulated conditions affected fibroblasts 
possessed an elevated level of p-SMAD2 protein detected by western blotting relative to normal cells, 
whereas p-SMAD3 protein levels did not differ (Figure 2G). The application of TGF-β1 (12.5 ng/ml) for 30 
and 60 min did not significantly increase p-SMAD3 levels relative to untreated normal cells (Figure 2G). 
Increased levels of p-SMAD2 in affected fibroblasts were not elevated further with TGF-β1 stimulation (Figure 
2G). 
LM lesions lack SMAD2 phosphorylation compared to scleroderma 
Following the discovery of variance in p-SMAD2 and 3 levels between LM fibroblasts harvested from normal 
and affected regions, differences in LM and scleroderma skin tissue was additionally investigated. 
Immunohistochemistry revealed widespread nuclear p-SMAD3 staining in the dermis of LM and scleroderma 
skin, both in the dermis and epidermis (Figure 3A). However, the presence of increased nuclear p-SMAD2 
was significantly more frequent in dermis of scleroderma skin compared to LM or normal skin (Figure 3B). 
Therefore, the reduced nuclear p-SMAD2 expression seen in LM may be diagnostic of the disease. 
Gene expression analysis indicates consistent changes in the LM fibroblast secretome 
To characterise the differences inherent in LM fibroblasts of affected lesions and normal skin, gene 
expression analysis was performed. Microarray gene expression analysis (normal 1, 2, 3, and affected 1, 2, 
3) was combined with RNA-Seq data (normal 4, 5, and affected 4, 5) which identified 39 significantly 
differentially expressed genes by at least 2-fold that were common to ≥ 4 of the 5 normal/affected pairs 
(Figure 4A). Organ development, morphogenesis, tissue development, and extracellular proteins were the 
only over-represented gene ontology (GO) groups determined by DAVID GO term enrichment (Figure 4B). 
Of the 39 differentially expressed genes, 9 were secreted proteins (Figure 4C). As the secretome of normal 
cells could rescue the disease-associated phenotype of LM lesion affected fibroblasts, the subset of 
differentially expressed genes encoding secreted factors was further examined for fibrosis-centric proteins 
such as those known to modulate TGF-β1 signalling or the extracellular matrix (Figure 4C). From this subset 
Sclerostin domain containing 1 (SOSTDC1), ADAM metallopeptidase with thrombospondin type 1 motif 8 
(ADAMTS8), and Fraser extracellular matrix complex subunit 1 (FRAS1) were chosen for further study (Table 
2, Figure 4D). 
Sostdc1 knockdown increases migration and reduces proliferation and TGF β1 response 
SOSTDC1 is a secreted antagonist of TGF-β superfamily members and a modulator of Wnt signalling, both 
pathways that promote fibrosis [15–17]. Immunofluorescence staining of SOSTDC1 in LM skin tissue 
revealed a reduced signal in fibroblasts of affected regions relative to normal fibroblasts (Figure 5A). 
Additionally, SOSTDC1 protein expression was reduced in both the lysate and conditioned media 
supernatant of affected fibroblasts in vitro relative to normal cells (Figure 5B). SOSTDC1 was secreted in 
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glycosylated form, and PNGaseF treatment was necessary to resolve secreted SOSTDC1 expression in 
conditioned medium.  
To study the effect of SOSTDC1 downregulation in LM fibroblasts, mouse NIH 3T3 fibroblasts were 
transfected with either a scrambled sequence shRNA control or Sostdc1 shRNA. Conditioned media 
supernatant harvested from Sostdc1 shRNA transfected NIH 3T3 cells possessed reduced levels of Sostdc1 
protein relative to scrambled shRNA transfected cells (Figure 5C). Sostdc1 shRNA transfected fibroblasts 
exhibited a relative reduction in cell number after 10 days of in vitro culture compared to scrambled shRNA 
transfected cells (Figure 5D). Fibroblasts transfected with Sostdc1 shRNA also demonstrated an increase in 
migration relative to the scrambled shRNA control (Figure 5E). MMP2 levels and activity were unchanged in 
Sostdc1 knockdown fibroblasts (Figure 5F). 
The influence of Sostdc1 knockdown on TGF-β1 downstream signalling was investigated by treating 
scrambled or Sostdc1 shRNA transfected NIH 3T3 fibroblasts with or without TGF-β1 (12.5 ng/ml) for 3 or 6 
h. Scrambled shRNA expressing controls exhibited increased p-SMAD2 protein in response to TGF-β1, 
whereas in Sostdc1 shRNA transfected cells following TGF-β1 stimulation SMAD2 phosphorylation was 
limited (Figure 5G). 
To investigate the result of Sostdc1 downregulation on fibroblast phenotype, NIH 3T3 cells were transfected 
with either scrambled or Sostdc1 shRNA, and treated with or without TGF-β1 (12.5 ng/ml) with an increasing 
duration of serum starvation (0, 2 or 24 h). In normal culture conditions Sostdc1 shRNA expressing fibroblasts 
possessed elevated levels of α-SMA relative to the respective scrambled shRNA control (Figure 5H). TGF-
β1 treatment of scrambled shRNA fibroblasts increased α-SMA levels relative to untreated scrambled shRNA 
cells, whereas TGF-β1 treatment of Sostdc1 shRNA fibroblasts reduced α-SMA relative to untreated Sostdc1 
shRNA cells (Figure 5H). 
FRAS1 protein expression is lost in LM fibroblasts and in the dermis of LM affected skin 
FRAS1 is an ECM protein that mediates epidermal-dermal adhesion and is capable of activating TGF-β family 
members [18–20]. FRAS1 protein was decreased in LM affected fibroblasts relative to normal cells, thereby 
reflecting the gene expression analysis results (Figure 6A). Immunofluorescence staining of FRAS1 in LM 
skin tissue ex vivo was reduced in dermal fibroblasts associated with LM lesions compared to normal sites. 
Furthermore, widespread staining of FRAS1 was seen in the dermis not localised to fibroblasts, whilst 
epidermal FRAS1 levels did not significantly change (Figure 6B). This suggests that secretion of FRAS1 into 
the dermis is significantly decreased in LM. 
Overexpression of ADAMTS8 induces smooth muscle actin expression in normal fibroblasts 
ADAMTS8 is a member of the ADAMTS family of secreted metalloproteases which are implicated in a diverse 
array of functions including migration, adhesion, proliferation and growth factor signalling [21,22]. ADAMTS8 
protein levels were increased in affected fibroblasts associated with LM lesions relative to fibroblasts 
harvested from normal sites (Figure 6C). Similarly, ADAMTS8 immunofluorescence staining was increased 
in LM affected fibroblasts relative to normal fibroblasts (Figure 6D). 
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To study the effect of ADAMTS8 expression on fibroblast phenotype, LM fibroblasts from normal regions 
were transduced with either an empty vector control or an ADAMTS8 overexpression vector. Fibroblasts 
overexpressing ADAMTS8 demonstrated an increase in ADAMTS8 protein relative to the empty vector 
control (Figure 6E). Protein levels of α-SMA were elevated following ADAMTS8 overexpression relative to 
the empty vector control and thereby emulated the increase observed in affected cells relative to normal 
fibroblasts (Figure 6E). 
DISCUSSION 
LM is a mosaic disease where cells present in normal skin and lesions possess a heterogeneous phenotype 
which is responsible for their separate histology and, consequently, pathology [2]. We show that LM affected 
fibroblasts possessed a distinct cell-intrinsic phenotype which is responsible for many aspects of disease 
pathology: increased proliferation, migration, MMP-2 activity, and decreased adhesion. These processes are 
integral to normal fibroblast function during wound healing and scar formation [23,24]; some of which are 
additionally involved in scleroderma [25,26]. Constitutive SMAD2 phosphorylation and subsequent 
insensitivity to TGF-β1 also contributed to the LM phenotype. Conditioned media swap experiments 
confirmed that the disease phenotype is driven by secreted proteins. Furthermore, a discrete set of 
differentially expressed genes, including downregulated SOSTDC1 and upregulated ADAMTS8, promoted 
different facets of the LM phenotype. It is important to consider when interpreting these experiments that 
there may be systemic effects caused by methotrexate treatment, although these should be controlled for by 
site matching in the same patient, or that there may be underlying genetics that predispose to LM. Both could 
change the biology of the fibroblasts even in the unaffected sites 
The finding herein of unaltered levels of TGF-β1 secretion between normal and affected fibroblasts agrees 
with studies investigating TGF-β1 in skin and blood of various forms of scleroderma [13,27]. Although no 
difference in TGF-β1 secretion existed between normal and affected fibroblasts, there was instead a distinct 
response to TGF-β1 in LM fibroblasts. The reduction in affected fibroblast proliferation with TGF-β1 
stimulation indicates a transition to the myofibroblast phenotype, where differentiation leads to a contractile 
phenotype whilst proliferation ceases [4]. This altered TGF-β1 responsiveness could be attributed to LM 
fibroblasts being skewed towards a myofibroblast phenotype, consistent with the increased α-SMA 
expression in resting affected fibroblasts, however there may be a stall in the differentiation to a full 
myofibroblast phenotype as contraction of collagen gels was impaired. It is possible that incomplete 
myofibroblast differentiation is contributing to the fibrotic phenotype in LM 
Canonical TGF-β1 signalling occurs through the phosphorylation and activation of SMAD2 and SMAD3 [5]. 
LM tissue displayed a distinct profile of SMAD phosphorylation exhibiting lower p-SMAD2 relative to 
scleroderma, whereas p-SMAD3 was similar between them. Localised scleroderma fibroblasts exhibit 
constitutive DNA-SMAD3 binding which was reflected herein [28]. In LM affected fibroblasts it was only 
SMAD2 that portrayed elevated phosphorylation in the resting state. The implication of this constitutive 
activation is seen in the elevated α-SMA and consequent myofibroblast phenotype. In human lung fibroblasts, 
unlike SMAD3, SMAD2 overexpression results in a TGF-β1-independent alteration of phenotype with an 
increase in α-SMA [29]. This reinforces SMAD2, not SMAD3 as a crucial mediator in the control of LM 
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fibroblast phenotype. When affected fibroblasts were stimulated into action by either scratch wounding or 
TGF-β1 treatment, levels of SMAD2 were lower relative to normal cells and this was also reflected in the 
reduced α-SMA. This suggests a defect in the ability of affected fibroblasts to respond to such stimuli. A 
further reason aside from a general dysregulation of SMAD signalling may be that myofibroblasts in dense 
cultures, such as those arising from the increased proliferation witnessed in affected LM fibroblasts, decrease 
α-SMA expression and de-differentiate into α-SMA-negative fibroblasts due to contact-induced 
desensitisation to TGF-β1 [30]. 
SOSTDC1 is an inhibitor of bone morphogenetic proteins (BMPs), which belong to the TGF-β superfamily, 
that prevents cognate receptor association by directly binding to BMPs [16,17]. SOSTDC1 is further indirectly 
related with TGF-β signalling through its interaction with the Wnt pathway which is activated in many fibrotic 
diseases [15,31,32]. Therefore, the decreased SOSTDC1 expression and secretion in LM represents a 
mechanism for the fibrosis, as inhibition of Wnt and SMAD signalling is lost. Sostdc1 knockdown caused a 
relative decrease in proliferation contrary to the elevated proliferation of LM affected fibroblasts. It is possible 
that the resulting disinhibition of TGF-β signalling promotes the fully differentiated, pro-contraction and anti-
proliferation myofibroblast phenotype [4]. However, the Sostdc1 shRNA was sufficient to induce the migratory 
phenotype of affected LM fibroblasts. This is consistent with the concept that LM fibroblasts are migratory, 
activated myofibroblast-like cells. 
The diminished p-SMAD2 response and limited α-SMA induction with TGF-β1 treatment of Sostdc1 
transfected fibroblasts mirrored the lack of responsiveness seen in affected LM fibroblasts. Therefore, 
reduced SOSTDC1 is likely a driver of TGF-β1 insensitivity in LM fibroblasts. As SOSTDC1 can affect both 
the TGF-β and Wnt signalling pathways, it is attractive to suggest that loss of SOSTDC1 or related genes 
can perturb myofibroblast differentiation to induce a pro-fibrotic dermal environment. Sostdc1 shRNA 
transfection reproduced the increase in MMP-2 activity and consequent fibroblast migration. However, 
transfection alone was insufficient to replicate the increase in MMP-2 protein secretion. Since MMP-2 can 
activate TGF-β1, this suggests that affected fibroblasts could experience a greater TGF-β1 response and 
SMAD2 phosphorylation without a change in TGF-β1 levels [12]. 
LM tissue and affected fibroblasts possessed a relative decrease in FRAS1 gene expression that was 
replicated at the protein level both in vitro and in LM skin tissue ex vivo. Mutations in FRAS1 are responsible 
for Fraser syndrome which is a severe multisystem condition that occurs during development in utero where 
45% of individuals are stillborn or die within a year, whilst those that survive are developmentally delayed 
[18,20]. Mutations in the Fras1 gene produce epidermal-dermal adhesion defects which manifests as large 
blisters [19]. This is caused by a defective ECM arising from a mid-gestational developmental defect 
potentially accompanied by a dysregulation of TGF-β signalling [18]. This is consistent with the significantly 
lower adhesion of affected LM fibroblasts. Moreover, affected fibroblast conditioned media decreased the 
adhesion of normal fibroblasts implicating a secreted factor, potentially FRAS1, in this facet of the LM 
phenotype. 
The diverse ADAMTS metalloprotease family are structurally similar to the MMP and ADAM proteases; 
accordingly, they possess similar and overlapping functionality [22,33]. The increased relative expression of 
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ADAMTS8 in affected fibroblasts was reproduced at the protein level. Elevated levels of ADAMTS8 in affected 
fibroblasts can help explain their enhanced motility as the greater ECM remodelling leads to a less dense 
matrix which would otherwise impede migration [11]. Upregulation of ADAMTS4 and ADAMTS5, which 
belong to the proteoglycanase sub-group alongside ADAMTS8, are involved in the over-degradation of 
cartilage ECM in osteoarthritis [11]. An analogous process could occur in LM, with ADAMTS8 upregulation 
being a factor in the observed tissue atrophy. In nasopharyngeal carcinoma cell lines expressing ADAMTS8, 
apoptosis was induced and this could potentially act synergistically with the above mechanism to contribute 
to the atrophy [22]. ADAMTSs are secreted and are capable of cleaving and activating growth factors that 
are embedded in the ECM such as TGF-β1; a process shared by MMPs, including MMP-2, which are also 
secreted [34,35]. In normal fibroblasts overexpressing ADAMTS8, α-SMA protein was induced which is 
consistent with an effect on TGF-β1 signalling. 
Overall, these data highlight the importance of the secretome in LM and normal secretome replacement or 
addition of normal cells in affected areas may be a relatively simple and viable treatment. An improved 
understanding of the function of the altered LM secretome will lead to viable targeted therapies capable of 
modulating TGF-β1 signalling with more control so as to prevent fibrosis and atrophy.
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Figure 1. LM affected fibroblasts are hyperproliferative, hypermigratory, with elevated collagen 
processing. A. Histology of LM affected lesion and site-matched normal skin stained with haemotoxylin and 
eosin; deep dermis denotes the reticular dermis distal from the epidermis. Bar 50 μm. B. Growth curve 
obtained from cell counts of primary human dermal fibroblasts isolated from LM affected lesions and site-
matched normal skin cultured in vitro for 10 days. C. BrdU incorporation measured by absorbance (450 nm) 
in confluent normal and affected fibroblasts. D. Representative cell motility (scratch) assay image of normal 
and affected fibroblasts where the monolayer was scratched following a 30 min pre-incubation with mitomycin 
C (10 μg/ml) to inhibit proliferation, and the denuded area measured after 24 h in the continued presence of 
mitomycin C. Bar 50 μm. Graph (right) shows denuded area normalised to denuded area at 0 h. E. Collagen 
gel contraction assay performed on normal and affected LM fibroblasts for 8 days. Graph (right) shows gel 
area normalised to gel area at day 0. F. TGF-β1 ELISA of conditioned media supernatant from overnight 
serum-starved normal and affected fibroblasts harvested after 24 h incubation. G. Representative western 
blot analysis (top) and zymography (bottom) of MMP-2 protein in lysates and conditioned media from normal 
and affected LM fibroblasts respectively. H. Graph of normalised MMP-2 activity in normal and affected 
conditioned media as measured by zymography  . *** P < 0.001, ** P < 0.01, * P < 0.05, Paired T-test. All 
data expressed as mean ± S.E.M. n=2 different normal and affected pairs. Representative data is shown. 
Figure 2. LM affected fibroblasts are insensitive to exogenous TGF-β1 and scratch wounding. A. BrdU 
incorporation in confluent normal and affected fibroblasts treated with TGF-β1 (12.5 ng/ml) or the control 
vehicle DMSO (0.1% v/v) for 24 h. B. Cell motility (scratch) assay of normal and affected fibroblasts after 24 
h incubation with or without media conditioned for 24 h from the opposite fibroblast type in the presence of 
mitomycin C (10 μg/ml) with a 30 min pre-incubation. Graph (right) shows mean denuded area normalised to 
denuded area at 0 h. C. Cell adhesion assay of normal and affected fibroblasts incubated for 24 h with media 
alone, or TGF-β1 (12.5 ng/ml), or media conditioned for 24 h with the opposite fibroblast type. Nucleic acid 
fluorescence is proportional to adherent cell number. * P < 0.05 vs normal, *** P < 0.001 vs normal, †† P < 
0.01 vs normal + TGF-β1, paired T-test. D. Representative immunofluorescence staining of SMAD2 in normal 
and affected fibroblasts in vitro 30 min post-scratch. E. Representative western blot of α-SMA (ACTA2) 
protein in normal and affected fibroblasts treated with or without TGF-β1 (12.5 ng/ml) for 24 h. GAPDH was 
used as a loading control. F. Representative immunofluorescence staining of α-SMA (ASMA) protein in 
normal and affected fibroblasts in vitro 24 h post-scratch. Bar 50 μm. G. Representative western blot analysis 
of p-SMAD2 and p-SMAD3 protein in normal and affected fibroblasts treated with TGF-β1 (12.5 ng/ml) for 30 
min and 60 min. GAPDH was used as a loading control. Graphs (bottom) show normalised densitometry 
values. * P < 0.05 vs normal (0 min), † P < 0.05 vs affected (0 min), Paired T-test. All data expressed as 
mean ± S.E.M. n=2 different normal and affected pairs. Representative data is shown. 
Figure 3. Lack of SMAD2 phosphorylation is diagnostic of LM. A. Representative p and p-SMAD2 
immunofluorescence and p-SMAD3 immunohistochemistry from the dermis of normal skin (n = 5), linear 
morphoea (n = 9), and scleroderma (n = 3). Bar 50 µm. B. Scoring of presence (black) or absence (white) of 
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nuclear p-SMAD2 and p-SMAD3 in the dermis of normal skin (Nor), linear morphoea (Mor) or scleroderma 
(Scl). * P < 0.05, Fisher’s exact test. 
Figure 4. Gene expression analysis of differentially expressed genes in LM. A. Heat map and cluster 
analysis of significantly (> 2 fold, P < 0.05 in ≥ 4 of 5 sample pairs) differentially expressed genes (DEG) of 
matched normal and affected pairs (n = 5; 3 by microarray, 2 by RNAseq). Yellow denotes upregulation, blue 
downregulation. B. Gene ontology (GO) groups over-represented from the differentially expressed genes in 
LM fibroblasts. Results displayed as 1/P value with Bonferroni correction for multiple testing. C. Mean fold 
change of differentially expressed secreted factors in LM fibroblasts. D. Pairwise investigation (N1 vs A1, N2 
vs A2, etc.) of ADAMTS8, FRAS1 and SOSTDC1 expression in 5 pairs of samples. P values are shown for 
Wilcoxon rank sum test. 
Figure 5. Sostdc1 knockdown increases migration, reduces proliferation, and causes TGF-β1 
insensitivity. A. Representative immunofluorescence staining of SOSTDC1 in normal and affected LM skin 
tissue ex vivo. B. Representative western blot analysis of SOSTDC1 protein in cell lysate and conditioned 
media supernatant from normal and affected LM fibroblasts cultured in vitro. GAPDH was used as a loading 
control. C. Representative western blot analysis of Sostdc1 protein in conditioned media supernatant from 
mouse NIH 3T3 fibroblasts transfected with either a scrambled sequence shRNA control or Sostdc1 shRNA, 
and processed with or without PNGase. Equal loading of conditioned medium was confirmed with Ponceau 
red (B, C). D. Growth curve of scrambled shRNA or Sostdc1 shRNA transfected NIH 3T3 fibroblasts cultured 
for 10 days. * P < 0.05 vs scrambled shRNA (day 10). E. Cell motility (scratch) assay of scrambled shRNA 
or Sostdc1 shRNA transfected NIH 3T3 fibroblasts after 24 h in the presence of mitomycin C (10 μg/ml) with 
a 30 min pre-incubation. Graph (bottom) shows denuded area normalised to denuded area at 0 h. * P < 0.05 
vs scrambled shRNA. F. NIH 3T3 fibroblasts transfected with either scrambled shRNA or Sostdc1 shRNA, in 
which lysates were subjected to gelatin zymography (top) or western blot analysis (bottom) of MMP-2. G. 
Representative western blot analysis of p-SMAD2 and SMAD2 protein in NIH 3T3 fibroblasts transfected with 
either scrambled shRNA or Sostdc1 shRNA, with or without TGF-β1 treatment (12.5 ng/ml) for 3 or 6 h. 
GAPDH was used as a loading control. H. Representative western blot analysis of α-SMA (ACTA2) protein 
in NIH 3T3 fibroblasts transfected with either scrambled shRNA or Sostdc1 shRNA, and treated with or 
without TGF-β1 (12.5 ng/ml) with increasing duration of serum starvation (0, 2 or 24 h). GAPDH was used 
as a loading control. All data expressed as mean ± S.E.M. unpaired T-test, n=3 biological replicates. 
Representative data is shown 
Figure 6. FRAS1 dermal expression is reduced in LM skin; ADAMTS8 overexpression induces smooth 
muscle actin expression. A. Representative western blot analysis of FRAS1 protein levels in normal and 
LM affected fibroblasts. GAPDH was used as a loading control. Graph (right) shows normalised FRAS1 
intensity. B. Representative immunofluorescence staining of FRAS1 in skin tissue harvested from LM 
affected lesions (n=9) and normal skin (n=5). Graph (bottom) shows fluorescence normalised to cell number. 
* P < 0.05, unpaired T-Test. C. Representative western blot analysis of ADAMTS8 protein levels in normal 
and LM affected fibroblasts. Graph (right) shows normalised ADAMTS8 intensity. D. Representative 
immunofluorescence staining of ADAMTS8 in primary dermal fibroblasts from LM affected lesions and site-
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matched normal skin. E. Representative western blot analysis of α-SMA (ASMA) and ADAMTS8 in normal 
(N) or LM affected (n=3 biological replicates) (A) fibroblasts and normal fibroblasts transduced with either an 
empty vector control or an ADAMTS8 overexpression vector. GAPDH was used as a loading control. All data 
expressed as mean ± S.E.M. 
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1 TABLES 
Table 1. Clinical characteristics of patients with LM 
Patient Sex Age 
(years) 
Biopsy 
site 
1 Female 10 Thigh 
2 Female 12 Knee 
3 Male 8 Lower leg 
4 Male 17 Thigh 
5 Female 10 Thigh 
Clinical characteristics of patients with LM from whom biopsies were obtained. Primary dermal fibroblasts 
were isolated from affected (A) lesions and site-matched normal (N) regions. All patients were on 
methotrexate at time of harvest. 
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Table 2. Differentially expressed genes in LM 
Gene 
Affymetrix RNA-Seq Affymetrix RNA-Seq Relative to N P 
value N1 N2 N3 N4 N5 A1 A2 A3 A4 A5 Log FC FC 
ADAMTS8 -1.71 -2.46 -2.67 -1.66 -1.66 3.06 1.71 3.05 1.66 1.66 4.26 19.15 0.00 
SLC14A1 -1.88 -1.64 -0.89 -1.66 -1.66 1.64 0.89 1.28 1.66 1.66 2.97 7.86 0.00 
EVI2A -0.93 -0.63 -1.51 NaN -1.98 2.16 0.63 0.84 NaN 1.98 2.66 6.34 0.00 
NOV -2.11 -2.28 -1.00 -0.84 0.57 2.56 1.13 1.00 0.84 -0.57 2.12 4.35 0.02 
CRIP1 -0.48 -1.92 -0.64 -0.79 NaN 0.48 0.59 1.08 0.79 NaN 1.69 3.23 0.01 
CD74 -0.83 -0.39 -0.42 -1.69 0.67 1.17 0.39 1.90 1.69 -0.67 1.43 2.69 0.05 
PPIL2 -0.50 -0.74 -0.64 NaN -0.55 0.66 0.50 0.71 NaN 0.55 1.21 2.32 0.00 
PPP1R13L 0.45 1.22 0.55 0.83 -0.54 -0.46 -0.56 -0.45 -0.83 0.54 -0.86 0.55 0.05 
PPAPDC1A 1.34 0.63 0.53 1.19 -0.67 -1.17 -0.71 -0.53 -1.19 0.67 -1.19 0.44 0.04 
EXPH5 0.38 1.37 0.67 0.96 -0.55 -0.38 -1.55 -1.73 -0.96 0.55 -1.38 0.38 0.03 
IL18R1 0.29 -0.28 0.28 1.66 1.51 1.41 -1.68 -1.67 -1.66 -1.51 -1.71 0.30 0.05 
KRT19 0.37 2.80 0.77 -0.70 1.58 -0.54 -2.47 -0.37 0.70 -1.58 -1.81 0.29 0.05 
WWC1 -0.16 1.83 0.16 0.90 1.66 0.82 -1.83 -1.22 -0.90 -1.66 -1.84 0.28 0.02 
AMIGO2 1.32 1.88 0.52 0.93 NaN -0.64 -1.00 -0.52 -0.93 NaN -1.93 0.26 0.00 
GRTP1 0.07 1.59 1.17 1.66 NaN -0.07 -1.05 -0.47 -1.66 NaN -1.93 0.26 0.01 
LHX8 1.43 -1.00 1.10 1.66 1.66 0.82 -2.17 -0.82 -1.66 -1.66 -2.07 0.24 0.02 
FRAS1 0.97 0.44 0.78 1.66 1.66 -0.89 -0.67 -0.44 -1.66 -1.66 -2.17 0.22 0.00 
BBOX1 1.45 3.29 -0.04 0.84 NaN 0.04 -0.77 -2.03 -0.84 NaN -2.28 0.21 0.04 
MDFI -0.02 1.17 0.02 1.66 NaN 0.08 -3.53 -1.48 -1.66 NaN -2.35 0.20 0.04 
COL22A1 0.78 3.67 0.25 NaN 0.87 -0.25 -1.08 -2.21 NaN -0.87 -2.50 0.18 0.04 
PI16 1.60 -1.57 1.06 2.31 2.48 1.26 -1.06 -2.20 -2.31 -2.48 -2.53 0.17 0.04 
CCL11 -0.58 2.20 0.58 1.66 1.66 1.02 -3.12 -2.05 -1.66 -1.66 -2.60 0.17 0.02 
F11R 0.98 4.25 -0.08 0.58 1.66 0.08 -1.89 -2.05 -0.58 -1.66 -2.70 0.15 0.02 
TPD52 0.83 2.69 0.85 0.61 1.66 -0.83 -3.43 -2.46 -0.61 -1.66 -3.12 0.11 0.00 
TMEM176B 0.84 3.66 0.77 0.72 NaN -0.77 -3.73 -1.35 -0.72 NaN -3.14 0.11 0.02 
TRIM29 1.28 4.71 0.09 NaN 0.74 -0.09 -2.49 -2.52 NaN -0.74 -3.16 0.11 0.05 
CXADR 1.24 4.30 -0.04 0.98 NaN 0.04 -1.87 -3.57 -0.98 NaN -3.21 0.11 0.04 
LIPG 1.06 3.47 -0.58 1.11 1.35 0.58 -3.47 -4.73 -1.11 -1.35 -3.30 0.10 0.02 
EFNA1 1.37 5.46 0.32 0.61 0.74 -0.32 -3.56 -2.83 -0.61 -0.74 -3.31 0.10 0.02 
LAMC2 0.83 3.96 -0.18 NaN 0.91 0.18 -3.53 -3.48 NaN -0.91 -3.32 0.10 0.04 
F2RL1 0.06 3.91 -0.06 1.66 NaN 1.02 -3.88 -3.46 -1.66 NaN -3.39 0.10 0.06 
ANXA8 1.22 4.58 0.05 NaN 1.68 -0.05 -2.89 -2.08 NaN -1.68 -3.56 0.08 0.03 
SOSTDC1 1.57 4.64 0.52 -1.05 1.66 -0.52 -4.52 -4.93 1.05 -1.66 -3.58 0.08 0.04 
TP63 1.30 5.15 0.46 NaN 1.66 -0.46 -1.73 -2.29 NaN -1.66 -3.68 0.08 0.03 
SFN 1.33 3.87 0.02 1.66 NaN -0.02 -3.39 -3.06 -1.66 NaN -3.76 0.07 0.01 
C19orf33 2.17 4.96 0.40 1.66 NaN -0.58 -0.40 -3.21 -1.66 NaN -3.76 0.07 0.02 
IL18 1.27 5.49 1.32 NaN 1.66 -1.27 -1.84 -2.25 NaN -1.66 -4.19 0.05 0.02 
KRT5 1.21 4.40 0.19 0.53 1.66 -0.19 -6.57 -7.22 -0.53 -1.66 -4.83 0.04 0.03 
KRT6 1.05 5.43 0.13 NaN 1.58 -0.13 -7.92 -5.53 NaN -1.58 -5.84 0.02 0.04 
Gene expression analysis by Affymetrix (N1, N2, N3, A1, A2, A3) and RNA-Seq (N4, N5, A4, A5) of LM 
normal (N) and affected (A) fibroblasts. 39 genes were significantly differentially expressed in ≥ 4 of 5 sample 
pairs. Data normalised and sorted by log fold change (FC). Yellow denotes upregulation, blue 
downregulation. NaN, not a number.
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